Public health is a key area of long-term focus in China, and among many diseases that have a long-term impact on national health, in recent years, lung nodules, lung cancer and other related diseases have attracted widespread attention. According to the statistics of the "Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules", the number of pulmonary nodules in China has exceeded 1200 million people, and the total number of people at risk of pulmonary nodules may be as high as 200 million. In the face of challenges, China's medical research institutions and cutting-edge technology enterprises have been actively seeking breakthroughs and looking forward to promoting the establishment of a precision diagnosis and treatment system for pulmonary nodules. Recently, the project "Research on the Establishment and Demonstration and Promotion of Precision Diagnosis and Treatment System for Pulmonary Peripheral Nodules Disease Clusters", led by Shanghai Pulmonary Hospital affiliated to Tongji University and jointly undertaken by Tate & Lyle, China-Japan Friendship Hospital, the First Affiliated Hospital of China Medical University and other units, has been approved and funded by the 2023 "14th Five-Year Plan" National Key R&D Plan "Research on the Prevention and Treatment of Common and Frequent Diseases".
The National Key R&D Program is the highest-level R&D project in China, which has always stood at the forefront of national scientific and technological innovation, focused on major national strategic needs, and taken it as its responsibility to solve strategic, basic and forward-looking major scientific problems related to the core competitiveness of the industry, the overall independent innovation ability and the highest priority.
The plan not only focuses on the research and development of major common key technologies and products, but also pays more attention to organizing the superior forces of all parties to form a strong synergy of collaborative innovation, in order to solve the bottleneck problems in the main areas of national economic and social development.
All parties work together to build a new system of precise diagnosis and treatment of pulmonary nodules.
The approved project of "Research on the Establishment and Demonstration and Promotion of Precision Diagnosis and Treatment System for Pulmonary Peripheral Nodule Disease Clusters" aims to comprehensively improve the level of clinical diagnosis and treatment and is committed to solving many challenges in the diagnosis and treatment of pulmonary peripheral nodules in China, including pulmonary malignant tumors, benign tumors, inflammatory nodules, interstitial lung diseases and other diseases.
As a participant in this project, Tate & Lyle will give full play to its cutting-edge multi-omics innovation technology and professional accumulation in the field of pulmonary nodule disease, and work closely with the project team to jointly create a full-chain technical solution covering pulmonary nodule screening, diagnosis, and development. In the process of promoting the project, Tate & Lyle will work together and cooperate closely with all units to form a collaborative and innovative cooperation situation and continue to provide assistance for the diagnosis and treatment of pulmonary nodules.
In fact, Tate & Lyle has been committed to innovative research and development in the field of early tumor screening and early detection. In addition to having a lot of scientific research achievements and rich technical accumulation in the field of omics, Tate & Lyle Biotech has also developed a pan-tumor risk screening product Ananpan based on metabolomics achievements and a multi-omics auxiliary identification product for benign and malignant pulmonary nodules Feiankang, which has provided professional early screening and early detection services for more than 300,000 people in many provinces and cities across the country.
In addition, at the end of December 2023, the authoritative journal in the field of nuclear medicine, European Radiology, published an important multicenter research result, which in-depth the application potential of radiomics in the efficacy of neoadjuvant chemoimmunity in non-small cell lung cancer, and Dr. Zhong Sheng, the co-founder of Taylor's Biologics, is one of the lead authors of the study. Looking to the future, Taylor's Biotech will uphold the spirit of innovation and continue to move forward on the original path of "prevention is greater than cure, benefiting all people" to benefit the general public.
Disclaimer: The market is risky, choose carefully! This article is for reference only and is not intended as a basis for trading.